Seres Therapeutics

$29.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.29 (-4.20%) Today

$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell MCRB and other stocks, options, and ETFs commission-free!

About MCRB

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA. The listed name for MCRB is Seres Therapeutics, Inc. Common Stock.

CEO

Eric D. Shaff

Employees

108

Headquarters

Cambridge, Massachusetts

Founded

2010

Market Cap

2.68B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

841.57K

High Today

$31.06

Low Today

$29.22

Open Price

$30.68

Volume

641.37K

52 Week High

$38.50

52 Week Low

$2.52

Collections

Analyst Ratings

75%

of 8 ratings

Buy

75%

Hold

25%

Sell

MCRB Earnings

-$0.59

-$0.39

-$0.20

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 2, Pre-Market